|  |
| --- |
| **Oral Antiviral Treatment Plan (COVID-19 & Influenza)****for residents of South Australian aged care facilities** |
|  |
| The risk of serious illness and death from respiratory viral illnesses including COVID-19 and Influenza increases with age and the rate is even higher for those with other chronic health conditions or a weakened immune system. Treatments for COVID mild illness and influenza are available and reduce the risk of progression to severe disease. Antiviral treatments must be commenced as soon as possible after diagnosis. All people over the age of 70 are eligible for COVID antiviral treatment. Assessing a person’s wishes regarding treatment and their antiviral treatment eligibility and suitability in advance facilitates the streamlined and safe commencement of oral antivirals as soon as possible after symptom onset or diagnosis. Residential Aged Care Facilities should notify the General Practitioner by phone as soon as possible within 24 hours of diagnosis of COVID or influenza. |
|  |
| **PART ONE (to be completed by GP with resident or their substitute decision maker)** |
|  |
| **Resident name:** |  | **Date:** |  |
|  |
| **Completed by** | **Name** | **Signature** |
| Doctor |  |  |
| Completed with patient |  |  |
| Completed with SDM |  |  |
|  |
| **In the event that you are diagnosed with COVID-19 or influenza do you wish to have antiviral treatment – with the goal of reducing the risk of progression to severe disease and hospitalisation? (Please refer Patient Information – COVID and Influenza Treatments)** |
| [ ]  Yes [ ]  No COVID oral antiviral - Molnupiravir (Lagevrio) [ ]  Yes [ ]  No COVID oral antiviral - Nirmatrelvir/Ritonavir (Paxlovid) – if suitable[ ]  Yes [ ]  No Influenza antiviral treatment - Oseltamivir (Tamiflu)[ ]  Yes [ ]  No Influenza antiviral prophylaxis (in the event of an outbreak in the RACF)[ ]  Yes [ ]  No I have been given written or verbal information regarding the above medications |

|  |
| --- |
| **In the event of deterioration due to COVID or influenza, what are your wishes?**  |
| *Please refer to Advance Care Directive when responding to this question* |
|  |
| **PART TWO (to be completed by GP)** |
|  |
| **ORAL ANTIVIRAL TREATMENT ELIGIBILITY AND SUITABILITY**This assessment will assist in determining which COVID-19 or influenza treatment (Paxlovid® or Lagevrio®) may be suitable for your patient, in accordance with their wishes. Refer to [PBS Eligibility Criteria](https://www.pbs.gov.au/info/news/2022/07/expanded-eligibility-criteria-for-covid-19-treatments%20), [SA Health COVID 19 Mild Illness Treatment and Referrals](https://www.sahealth.sa.gov.au/wps/wcm/connect/public%2Bcontent/sa%2Bhealth%2Binternet/conditions/infectious%2Bdiseases/covid-19/health%2Bprofessionals/monoclonal%2Bantibody%2Binfusion%2Bapplication%2Bfor%2Bcovid-19%2Bpositive%2Bpatients) and [NPS COVID Oral Antivirals in Residential Aged Care](https://www.nps.org.au/coronavirus/faqs-covid-19-antivirals-in-racfs%23%3A~%3Atext%3DNPS%20MedicineWise%2Cupdated%20as%20clinical%20experience%20expands.). |
|  |
| **Age 70 years and above? If yes, eligible for COVID-19 oral antiviral treatments on the PBS** [ ] Yes [ ] No |
| **OR** |
| **Age 50-69 years (or 30 years for Aboriginal or Torres Strait Islander) with 2 risk factors below?** **If Yes, eligible for COVID-19 oral antiviral treatments on the PBS.** [ ] Yes [ ] No |
| [ ]  Living in RACF [ ]  Disability with multiple comorbidities and/or frailty[ ]  Neurological conditions, including stroke and dementia and demyelinating conditions[ ]  Respiratory compromise, including COPD, moderate or severe asthma (required inhaled steroids), and bronchiectasis, or caused by neurological or musculoskeletal disease, [ ]  Heart failure, coronary artery disease, cardiomyopathies [ ]  Obesity (BMI greater than 30 kg/m2)[ ]  Diabetes type I or II, requiring medication for glycaemic control[ ]  Renal impairment (eGFR less than 60mL/min)[ ]  Cirrhosis[ ]  Reduced, or lack of, access to higher level healthcare and lives in an area of geographic remoteness  classified by the [Modified Monash Model](https://www.health.gov.au/health-topics/rural-health-workforce/classifications/mmm) as Category 5 or above.**OR****Age 18 years and above with moderate to severe immunocompromise? If Yes, eligible for COVID-19 oral antivirals on the PBS.** [ ] Yes [ ] No |
| **Ability to swallow oral medicines whole** | [ ] Yes [ ] No Paxlovid® cannot be crushed, Lagevrio® capsules can be opened. |
| **Most recent eGFR (last 6 months):**eGFR = \_\_\_\_\_\_\_\_\_\_\_\_Date \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | [ ]  ≥60mL/min[ ]  30-59mL/min (Dose adjustment recommended for Paxlovid®)[ ]  <30mL/min (Paxlovid® contraindicated) [ ]  No recent eGFR  |
| **Does the patient have severe liver disease? (Child-Pugh Class C)**  | [ ]  Yes [ ]  No If Yes, Paxlovid® contraindicated  |
| **Currently on medications with potential to interact with Paxlovid®**  | [ ] Yes [ ] No [ ]  UnsureRefer to <https://www.covid19-druginteractions.org/><https://www.veteransmates.net.au/topic-68-therapeutic-brief> |
| **What is the plan for treatment?**E.g. Paxlovid® suitable but changes to regular medications required (**provide details**); Paxlovid® with renal dose adjustment; molnupiravir (Lagevrio®). |  |

If oral antivirals are not suitable for your patient and they wish to consider infusion treatment please refer to [SA Health COVID Mild Illness Treatments and Referrals](https://www.sahealth.sa.gov.au/wps/wcm/connect/public%2Bcontent/sa%2Bhealth%2Binternet/conditions/infectious%2Bdiseases/covid-19/health%2Bprofessionals/monoclonal%2Bantibody%2Binfusion%2Bapplication%2Bfor%2Bcovid-19%2Bpositive%2Bpatients).

If you require further advice regarding COVID oral antiviral prescribing please call the SA Health dedicated COVID -19 Clinical Medical Advice Line or email health.COVIDDoctorInfo@sa.gov.au.